ASAS HEALTH INDEX: VALIDITY AND RELIABILITY IN ARGENTINEAN PATIENTS WITH SPONDYLOARTHRITIS

V.M. Duarte, U. Kiltz, V. Navarro-Compán, N. Lloves, G. Crespo Amaya, L. Ferreyra, C. Orozco, E.E. Schneeberger, H. Maldonado Ficco, D. Baenas, F. Colombres, M. Mamani, J.A. Maldonado Cocco, E. SorianoHospital B. Rivadavia, Buenos Aires, Argentina Rheumazentrum Ruhrgebiet, Herne, Germany Hospital la Paz, IdiPaz, Madrid, Spain Hospital Italiano de Buenos Aires Instituto de Rehabilitaciόn Psicofísica (IREP), Buenos Aires Hospital San Antonio de Padúa, Río Cuarto Hospital Privado de Cόrdoba, Cόrdoba Hospital de Clínicas Dr. Avellaneda, Tucumán Consulting Profesor of Rheumatology, University of Buenos Aires, Buenos Aires, ArgentinaObjectives: The aim of the study was to translate and validate the ASAS Health Index (ASAS-HI) for Argentinean patients with spondyloarthritis. Methods: Translation was done using a forward-backward procedure and qualitative interview were done with the translation. Patients fulfilling ASAS classification criteria for either axial (axSpA) or periphereal SpA (pSpA) were included to test psychometric properties. Test-retest reliability was assessed by intraclass correlation coefficient (ICC) in patients without treatment changes (stable disease state). In patients who required therapeutic modifications due to changes of disease activity, responsiveness was evaluated using a standardized response mean (SRM). Construct validity against other health outcomes was evaluated by Spearman correlation. Internal consistency (Cronbach-alfa) and discriminative ability between ASAS-HI and ASDAS were assessed. Results: Translation into Argentinean Spanish was accepted with minor changes. Fifty two patients were recruited [65% male, mean (SD) age 39. 5 (12.5) years and median (IQR) disease duration 72 (45–138) months]. Most of the patients had axSpA diagnosis (AS: 26, nr-axSpA: 18) while the rest had pSpA (8). The total score of the ASAS-HI was 7.4 (SD: 4.4), BASDAI: 4.4 (SD: 2.7), BASFI: 4.0 (SD: 3.1), ASDAS-CRP: 2.4 (SD: 0.9). Test-retest reliability (n: 20) was good ICC: 0.88 (95%IC 0.76 to 0.98). Sensitivity to change was tested in 13 patients and SMR was -0.61 for those patients receiving TNF inhibitors (n: 11). Convergent validity ranged as hypothesized with Spearman correlations from low (age: 0.27) to good (pain: 0.65), (table 1). The ASAS-HI discriminated well between patients with different stages of disease activity and function irrespective of the measure applied (ASDAS, BASDAI and BASFI) (table 2). The internal consistency according to Cronbach's alfa was 0.81. Table 1. Spearmen correlation coefficient CharacteristicsSpearmen correlation coefficient ASAS-HI (0–17)p value Age0.27<0.05 Pain (0–10)0.65<0.001 Night spinal pain (0–10)0.54<0.001 ASDAS0.51<0.001 BASDAI (0–10)0.60<0.001 BASFI (0–10)0.54<0.001 SF-36 Total0.46<0.001 Table 2. ASDAS Status Groups ASDAS Status Groups Inactive (n: 9)Moderate (n: 9)High (n: 29)very high (n: 5) ASAS-HI (0–17)3.44 (± 3.9)5.77 (± 4.79)9. 06 (± 3.49)10.05 (± 4.5) BASFI (0–10)0,53 (± 0,35)1.41 (± 1.40)5.5 (± 2.46)6.46 (± 3.12) BASDAI (0–10)1.21 (± 0.49)2.37 (± 1.7)5.73 (± 1.91)6.46 (± 3.38) Conclusions: The Argentinean version of the ASAS-HI was comprehensive and reliable by patients with SpA. The ASAS-HI is a valid tool for assessing overall functioning and health in spondyloarthritis. References: The ASAS Health Index (ASAS HI)a new tool to assess the health status of patients with spondyloarthritis, Clin Exp Rheumatol 2014;32:S105-S108. Disclosure of Interest: V. Duarte Employee of: Novartis Argentina, U. Kiltz: None declared, V. Navarro-Compán: None declared, N. Lloves: None declared, G. Crespo Amaya: None declared, L. Ferreyra: None declared, C. Orozco: None declared, E. Schneeberger: None declared, H. Maldonado Ficco: None declared, D. Baenas: None declared, F. Colombres: None declared, M. Mamani: None declared, J. Maldonado Cocco: None declared, E. Soriano: None declared DOI: 10.1136/annrheumdis-2017-eular.4386Citation: Annals of the Rheumatic Diseases, volume 76, supplement 2, year 2017, page 933Session: Spondyloarthritis - clinical aspects (other than treatment) (Poster Presentations )